PL1760089T3 - Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa - Google Patents

Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa

Info

Publication number
PL1760089T3
PL1760089T3 PL05019255T PL05019255T PL1760089T3 PL 1760089 T3 PL1760089 T3 PL 1760089T3 PL 05019255 T PL05019255 T PL 05019255T PL 05019255 T PL05019255 T PL 05019255T PL 1760089 T3 PL1760089 T3 PL 1760089T3
Authority
PL
Poland
Prior art keywords
molecules
tumour
present
relates
hla
Prior art date
Application number
PL05019255T
Other languages
English (en)
Inventor
Harpreet Singh
Niels Emmerich
Steffen Walter
Toni Weinschenk
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of PL1760089T3 publication Critical patent/PL1760089T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL05019255T 2005-09-05 2005-09-05 Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa PL1760089T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05019255A EP1760089B1 (en) 2005-09-05 2005-09-05 Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine

Publications (1)

Publication Number Publication Date
PL1760089T3 true PL1760089T3 (pl) 2010-03-31

Family

ID=35149455

Family Applications (2)

Application Number Title Priority Date Filing Date
PL05019255T PL1760089T3 (pl) 2005-09-05 2005-09-05 Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa
PL06777167T PL1922334T3 (pl) 2005-09-05 2006-09-05 Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów HLA i związana z nimi szczepionka przeciwnowotworowa

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL06777167T PL1922334T3 (pl) 2005-09-05 2006-09-05 Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów HLA i związana z nimi szczepionka przeciwnowotworowa

Country Status (23)

Country Link
US (1) US20090274714A1 (pl)
EP (2) EP1760089B1 (pl)
JP (1) JP5132561B2 (pl)
KR (1) KR101150663B1 (pl)
CN (1) CN101287755B (pl)
AT (2) ATE440107T1 (pl)
AU (1) AU2006289289B2 (pl)
BR (1) BRPI0615466A2 (pl)
CA (1) CA2621414C (pl)
CY (2) CY1110536T1 (pl)
DE (2) DE602005016112D1 (pl)
DK (2) DK1760089T3 (pl)
EA (1) EA013466B1 (pl)
ES (2) ES2330013T3 (pl)
HR (1) HRP20110240T1 (pl)
NO (1) NO20081690L (pl)
NZ (1) NZ565956A (pl)
PL (2) PL1760089T3 (pl)
PT (2) PT1760089E (pl)
RS (1) RS51893B (pl)
SI (2) SI1760089T1 (pl)
UA (2) UA97095C2 (pl)
WO (1) WO2007028573A1 (pl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1806358E (pt) 2005-09-05 2010-05-28 Immatics Biotechnologies Gmbh Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
ES2321680B1 (es) * 2007-04-26 2010-03-05 Fundacion Para La Investigacion Biosanitaria De Andalucia Oriental - Alejandro Otero (Fibao) Restauracion de las moleculas hla de clase i mediante terapia genica empleando vectores adenovirales portando el gen de la beta 2-microglobulina.
SI2567707T1 (sl) 2007-07-27 2017-01-31 Immatics Biotechnologies Gmbh Sestava s tumorjem povezanih peptidov in zadevnih cepiv proti raku
CA2694805C (en) * 2007-07-27 2014-09-09 Immatics Biotechnologies Gmbh Immunogenic epitopes of tumour-associated antigens
PT2660248E (pt) 2007-07-27 2015-10-12 Immatics Biotechnologies Gmbh Nova imunoterapia para tumores neuronais e cerebrais
CY1112212T1 (el) * 2008-04-24 2015-12-09 Immatics Biotechnologies Gmbh Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια
PT2113253E (pt) * 2008-04-30 2010-06-15 Immatics Biotechnologies Gmbh Formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) para vacinas
NO2119726T3 (pl) 2008-05-14 2015-05-23
AU2016204712B2 (en) * 2008-10-01 2018-03-01 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including neuronal and brain tumors
PT2172211E (pt) 2008-10-01 2015-03-09 Immatics Biotechnologies Gmbh Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) * 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
AU2011336019B2 (en) * 2010-12-02 2016-07-07 Oncotherapy Science, Inc. TOMM34 peptides and vaccines including the same
WO2013005164A2 (en) * 2011-07-05 2013-01-10 Cadila Pharmaceuticals Limited Cancer antigen
MY170949A (en) * 2011-07-11 2019-09-20 Cancer Res Initiatives Foundation A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine
CA2877933A1 (en) 2012-06-27 2014-01-03 Yuri Bushkin Rapid assays for t-cell activation by rna measurements using flow cytometry
US20140017267A1 (en) * 2012-07-13 2014-01-16 Matthias W Rath Metalloproteinase oligopeptides and their therapeutic use
TWI777194B (zh) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(一)
EP3369432A1 (en) 2013-12-09 2018-09-05 Targovax Asa A peptide mixture
PT3626729T (pt) 2014-12-23 2021-11-03 Immatics Biotechnologies Gmbh Novos péptidos e combinações de péptidos para uso na imunoterapia contra o carcinoma hepatocelular (chc) e outros cancros
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
MY190083A (en) 2015-03-17 2022-03-25 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
PT3388075T (pt) 2015-03-27 2023-08-18 Immatics Biotechnologies Gmbh Novos péptidos e combinações de péptidos para uso em imunoterapia contra vários tumores
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201510771D0 (en) * 2015-06-19 2015-08-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
EA201792531A1 (ru) 2015-06-19 2018-05-31 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии и способы получения каркасов для применения при лечении рака поджелудочной железы и других видов рака
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
ZA201707555B (en) 2015-06-25 2018-11-28 Immatics Biotechnologies Gmbh Novel cell epitopes and combination of cell epitopes for use in the immuno-therapy of myeloma and other cancers
IL308735A (en) 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh New peptides and combinations of peptides used in immunotherapy against ovarian cancer and other types of cancer
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511792D0 (en) 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
EP4321172A2 (en) 2015-07-06 2024-02-14 immatics biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
MY189596A (en) 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
MY198087A (en) 2015-10-05 2023-07-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
EP3167898A1 (en) 2015-11-11 2017-05-17 IEO - Istituto Europeo di Oncologia Srl Method for obtaining tumor peptides and uses thereof
EP3419656A4 (en) * 2016-02-22 2019-10-30 Oceanside Biotechnology NEOANTIGEN COMPOSITIONS AND THEIR METHODS OF USE IN IMMUNO-ONCOTHERAPY
BR112018070183A2 (pt) * 2016-03-31 2019-04-16 Neon Therapeutics, Inc. neoantígenos e métodos de seu uso
TW202304970A (zh) * 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
CN106986932A (zh) * 2017-04-06 2017-07-28 海口市人民医院 一种c‑Met表位肽及其应用
MY182816A (en) * 2018-02-15 2021-02-05 National Univ Corporation Asahikawa Medical Univ Cancer antigen peptide
CN110804642B (zh) * 2019-09-10 2022-06-21 清华大学 Gpr174免疫学功能及其用途
CN114641315A (zh) * 2019-11-14 2022-06-17 博阿济吉大学 癌症免疫疗法中的asc斑点
CN114524870A (zh) * 2020-11-23 2022-05-24 香雪生命科学技术(广东)有限公司 源自于ssx2抗原的短肽
WO2022226535A1 (en) * 2021-04-23 2022-10-27 Flow Pharma Inc. Vaccine for sars-cov-2
CN114478711A (zh) * 2022-01-05 2022-05-13 成都朗谷生物科技股份有限公司 一种针对乙型肝炎病毒的抗原肽及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
FI86437C (fi) 1978-12-22 1992-08-25 Biogen Inc Foerfarande foer framstaellning av polypeptider med de antigena egenskaperna hos ett hepatitis b- virusantigen.
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
DE69332485T2 (de) * 1992-08-11 2003-11-13 Harvard College Immunmodulierende peptide
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
WO1996003144A1 (en) 1994-07-27 1996-02-08 The Council Of The Queensland Institute Of Medical Research Polyepitope vaccines
PT879282E (pt) 1996-01-17 2003-11-28 Imp College Innovations Ltd Imunoterapia utilizando linfocitos t citotoxicos (ctl)
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6316213B1 (en) * 1997-03-19 2001-11-13 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian, breast and lung cancer
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
DE19917195B4 (de) 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
KR100358068B1 (ko) * 1999-12-28 2002-10-25 주식회사 하이닉스반도체 플래쉬 메모리 소자의 제조방법
WO2004014867A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Matrix metalloproteinase inhibitors and methods for identification of lead compounds
US20060045881A1 (en) * 2004-08-26 2006-03-02 Board Of Regents, The University Of Texas System Anti-cancer vaccines

Also Published As

Publication number Publication date
AU2006289289A1 (en) 2007-03-15
KR20080052647A (ko) 2008-06-11
CA2621414A1 (en) 2007-03-15
KR101150663B1 (ko) 2012-05-25
SI1760089T1 (sl) 2009-12-31
PT1760089E (pt) 2009-10-19
ES2330013T3 (es) 2009-12-03
DE602006019446D1 (de) 2011-02-17
HRP20110240T1 (en) 2011-05-31
DK1760089T3 (da) 2009-11-16
ES2358802T3 (es) 2011-05-13
EP1922334B1 (en) 2011-01-05
NO20081690L (no) 2008-04-04
AU2006289289B2 (en) 2012-04-19
UA97095C2 (ru) 2012-01-10
DK1922334T3 (da) 2011-04-18
EP1922334A1 (en) 2008-05-21
CA2621414C (en) 2016-10-04
NZ565956A (en) 2011-06-30
CN101287755B (zh) 2014-12-31
WO2007028573A1 (en) 2007-03-15
PT1922334E (pt) 2011-04-01
JP2009506762A (ja) 2009-02-19
EP1760089A1 (en) 2007-03-07
CN101287755A (zh) 2008-10-15
EA013466B1 (ru) 2010-04-30
SI1922334T1 (sl) 2011-04-29
ATE440107T1 (de) 2009-09-15
EP1760089B1 (en) 2009-08-19
JP5132561B2 (ja) 2013-01-30
UA105210C2 (ru) 2014-04-25
US20090274714A1 (en) 2009-11-05
PL1922334T3 (pl) 2011-06-30
WO2007028573A9 (en) 2008-05-02
CY1110536T1 (el) 2015-04-29
DE602005016112D1 (de) 2009-10-01
EA200800676A1 (ru) 2008-08-29
CY1113062T1 (el) 2016-04-13
RS51893B (en) 2012-02-29
ATE494303T1 (de) 2011-01-15
BRPI0615466A2 (pt) 2011-05-17

Similar Documents

Publication Publication Date Title
HK1220709A1 (zh) 混雜地結合於人類白細胞抗原 類分子的腫瘤相關肽
HRP20110240T1 (en) Tumor-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine
PL1794190T3 (pl) Immunogenne epitopy komórek pomocniczych T pochodzące z ludzkich antygenów nowotworowych oraz sposoby stosowania tych epitopów w immunoterapii